Truxima (rituximab), Celltrion’s MabThera biosimilar, became the first oncology monoclonal antibody biosimilar to enter the European market in April 2017. Two months later, Sandoz’s Rixathon, a second MabThera biosimilar, launched in Europe. In this series, we track awareness and uptake of Truxima and Rixathon since launch, to understand how their entry will impact the NHL, CLL, and immune biologics market. Along with awareness, familiarity, and perception of Truxima and Rixathon, our analysis also looks at the drivers and barriers behind uptake of these agents. Promotional efforts are explored, as well as prescriber and nonprescriber profiles, and benchmarking against other biosimilars, to better understand the dynamics of the German biosimilars market.

Questions Answered:

  • Are German physicians aware of Truxima and Rixathon?
  • What are the drivers to prescribing Truxima and Rixathon? What is the current level of Truxima and Rixathon use, and how is that changing over time?
  • Has experience with Truxima and Rixathon changed physicians’ opinion of biosimilars?
  • Have physicians experienced pressure to prescribe Truxima and Rixathon to patients?
  • What promotional messages are sales representatives employing for Truxima, Rixathon, and MabThera?

Table of contents

  • Biosimilars - Emerging Biosimilars - Oncology & Immunology: Truxima/Rixathon Launch Tracking (Germany) Wave 2

Author(s): Hamzah Aideed, M.Sc.

Hamzah Aideed is a Principal Analyst in the biosimilars team at Decision Resources Group. Hamzah’s responsibilities include conducting primary and secondary market research, generating key insights into biosimilars and the biopharmaceutical industry, and providing client support. His work in biosimilars encompasses four key therapy areas – immunology, oncology, endocrinology, and nephrology.

Prior to joining DRG, Hamzah was a Senior Research Executive at Consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies, for bespoke ad-hoc consulting projects. He holds an M.Sc. in Biotechnology & Business Management from the University of Warwick and a B.Sc. in Biological Chemistry from Aston University.


Related Reports

Biosimilars - Market Events And Forecast - Oncology

In 2018, sales of branded monoclonal antibody biologics in oncology exceeded $20 billion across the major markets (United States, EU5, and Jap...

View Details

Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 1

Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the seco...

View Details

Oncology Clinical Trial Monitor - Clinical Trials - Oncology Clinical Trial Monitor

Oncology Clinical Trial Monitor is a continuously updated dashboard, highlighting the global immuno-oncology clinical development landscape and clinical outcomes for key standards of care. This dyn...

View Details

Biomarkers In Oncology - Access & Reimbursement - Detailed, Expanded Analysis: Multi-indication (US)

Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant mela...

View Details